ANSWERS TO

FREQUENTLY ASKED QUESTIONS

NEXIUM Direct

NEXIUM Direct is a convenient, reliable way for your patients to get branded NEXIUM. NEXIUM Direct was designed with patients in mind and includes 24-hour support, automatic refills, and free home delivery to ensure your patients continue to get the proven healing Purple Pill. Best of all, most patients pay no more than $15 a month.*

*Automatically processed standard NEXIUM savings offer without requiring the savings card.

Simply instruct them to enroll by visiting NEXIUMDirect.com. Patients will need to get a valid prescription for NEXIUM, which can be sent directly to Eagle Pharmacy, an AstraZeneca Pharmacy administrator. This prescription can be sent via mail, phone, fax or ePrescribed from the physician’s office.

 

ePrescribe

NCPDP #: 5711975

NPI #: 1487905840

 

Phone/Fax

P: 1-800-4-NEXIUM

F: 1-877-283-9172

 

Mail

AstraZeneca Direct

c/o Eagle Pharmacy

PO Box 90789

Lakeland, FL 33804

Through the NEXIUM Direct program patients whose insurance co-pay is $140 or less for a 30-day supply will pay $15. Patients with a co-pay over $140 will receive a $125 discount off their co-pay. Cash-paying patients will receive a $125 contribution to their total cash price for NEXIUM. Taxes may apply. Standard shipping is free.

NEXIUM Direct is not available for prescriptions purchased under Medicaid or other similar state or federal government programs (ie, Tricare, Dept. of Defense, Dept. of Veterans Affairs). Patients with a valid prescription for NEXIUM are eligible for the NEXIUM Direct program, including patients with commercial or Medicare Part D insurance coverage and patients without insurance. There is no qualification process, nor is a savings card or coupon needed. AstraZeneca reserves the right to change or discontinue this offer at any time without notice.

For more information about the NEXIUM Direct program please go to NEXIUMDirect.com. You can also call 1-800-4-NEXIUM to contact NEXIUM Direct Customer Service, available 24 hours a day, 7 days a week, or send an e-mail to AstraZenecaDirect@eaglepharmacy.com for answers to your questions.

NEXIUM Direct is operated by AstraZeneca Direct, a program that delivers AstraZeneca brand name medications directly to patients. AstraZeneca is the maker of NEXIUM. Prescriptions are processed and handled by the AstraZeneca Direct pharmacy administrator, Eagle Pharmacy. Eagle Pharmacy is staffed by registered pharmacists and certified pharmacy technicians.

Dosage & Administration

Flexible administration options for NEXIUM include:

  • NEXIUM I.V. for Injection
  • NEXIUM for Delayed-Release Oral Suspension
  • NEXIUM Delayed-Release Capsules

Find out more about Dosage & Administration for NEXIUM.

Healing of erosive esophagitis (EE): NEXIUM 20 mg or NEXIUM 40 mg, once daily for 4 to 8 weeks, is recommended for short-term treatment for healing and symptomatic resolution of diagnostically confirmed EE.1

Maintenance of healing of EE: NEXIUM 20 mg, once daily, is recommended to maintain symptom resolution and healing of EE.1 Controlled studies did not extend beyond 6 months.

Symptomatic GERD: NEXIUM 20 mg, once daily for 4 to 8 weeks, is recommended for the short-term treatment of heartburn and other symptoms associated with GERD.1

For the full recommended dosing schedule of NEXIUM, visit Dosage & Administration for NEXIUM.

Reference 

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

In infants 1 month to less than 1 year, NEXIUM is indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD: for infants whose weight is 3 kg to 5 kg, the recommended dose is 2.5 mg once daily for up to 6 weeks; for infants whose weight is greater than 5 kg to 7.5 kg, the recommended dose is 5 mg once daily for up to 6 weeks; for infants whose weight is greater than 7.5 kg to 12 kg, the recommended dose is 10 mg once daily for up to six weeks.

For the short-term treatment (up to 8 weeks) of symptomatic GERD in patients 1 to 11 years of age: the recommended dose of NEXIUM is 10 mg once daily.1

For the short-term treatment in the healing of EE in patients 1 to 11 years of age: for children whose weight is less than 20 kg, the recommended dose is 10 mg once daily for up to 8 weeks; for children whose weight is 20 kg or greater, the recommended dose is 10 mg or 20 mg once daily for up to 8 weeks.1

For the short-term treatment (up to 4 weeks) of GERD in patients 12 to 17 years of age: the recommended dose of NEXIUM is 20 mg or 40 mg once daily.1

For patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the NEXIUM Delayed-Release Capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately. The granules should not be chewed or crushed. The granules/applesauce mixture should not be stored for future use.1

For patients who have a nasogastric tube in place, NEXIUM Delayed-Release Capsules can be opened and the intact granules emptied into a 60 mL catheter-tipped syringe and mixed with 50 mL of water. It is important to only use a catheter tipped syringe when administering NEXIUM through a nasogastric tube. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a nasogastric tube and deliver the contents of the syringe through the nasogastric tube in the stomach. After administering the granules, the nasogastric tube should be flushed with additional water. Do not administer the granules if they have dissolved or disintegrated. The suspension must be used immediately after preparation.1

Find out more about Dosage & Administration for NEXIUM.

Reference

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.







Patients should follow these instructions for taking NEXIUM:

  • Take NEXIUM exactly as prescribed by your doctor
  • Do not change your dose or stop NEXIUM without talking to your doctor
  • Take NEXIUM at least 1 hour before a meal
  • Swallow the capsules whole. Do not chew or crush them. For patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the NEXIUM Delayed-Release Capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The granules should not be chewed or crushed. The granules/applesauce mixture should not be stored for future use
  • If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose on time. Do not take a double dose to make up for the missed dose
  • If you take too much NEXIUM, consult with your doctor right away
  • If you take NEXIUM Delayed-Release Oral Suspension:
    • Empty the contents of a packet into a container with 1 tablespoon of water
    • Stir
    • Leave 2 to 3 minutes to thicken
    • Stir and drink within 30 minutes
    • If any medicine remains after drinking, add more water, stir, and drink right away

Find out more about Dosage & Administration for NEXIUM and read the full Prescribing Information for NEXIUM.

For patients with GERD with a history of erosive esophagitis, the recommended adult dose is either 20 or 40 mg of esomeprazole given once daily by intravenous injection (no less than 3 minutes) or intravenous infusion (10 to 30 minutes). Safety and efficacy of NEXIUM I.V. for Injection as a treatment for GERD patients with EE for more than 10 days have not been demonstrated.

NEXIUM I.V. for Injection should not be administered concomitantly with any other medications through the same intravenous site and/or tubing. The intravenous line should always be flushed with either 0.9% Sodium Chloride Injection USP, Lactated Ringer’s Injection USP, or 5% Dextrose Injection USP both prior to and after administration of NEXIUM I.V. for Injection.

When oral therapy is possible and appropriate, intravenous therapy with NEXIUM I.V. for Injection should be discontinued and the therapy should be continued orally.

Find out more about NEXIUM I.V. for Injection and read the full Prescribing Information  for NEXIUM I.V.

Reference

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Maintenance of healing of EE: NEXIUM 20 mg, once daily, is recommended to maintain symptom resolution and healing of EE.1 Controlled studies did not extend beyond 6 months.

Find out more about Dosage & Administration for NEXIUM.







Reference

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Clinical Data

In 7 different studies vs omeprazole,* lansoprazole, or pantoprazole (n>16,000, of whom >8000 received NEXIUM), NEXIUM demonstrated excellent erosive esophagitis (EE) healing rates.1–7



*In 2 of those studies, NEXIUM vs omeprazole, P=NS.

View healing data for NEXIUM vs omeprazole and lansoprazole 

References

  1. Richter JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001;96:656–665.
  2. Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14:1249–1258.
  3. Schmitt C, Lightdale CJ, Hwang C, et al. Dig Dis Sci. 2006;51:844–850.
  4. Lightdale CJ, Schmitt C, Hwang C, et al. Dig Dis Sci. 2006;51:852–857.
  5. Castell DO, Kahrilas PJ, Richter JE, et al. Am J Gastroenterol. 2002;97:575–583.
  6. Fennerty MB, Johanson JF, Hwang C, et al. Aliment Pharmacol Ther. 2005;21:455–463.
  7. Labenz J, Armstrong D, Lauritsen K, et al. Aliment Pharmacol Ther. 2005;21:739–746.

In one study, healing rates in GERD patients with varying degrees of LA grades A-D of erosive esophagitis (EE)* through 8 weeks were 94% NEXIUM 40 mg vs 84% omeprazole 20 mg (n=2425; P<.001).†1,2



In another study, healing rates in GERD patients with varying grades of EE* through 8 weeks were 94% NEXIUM 40 mg (P<.001 vs omeprazole 20 mg) vs 90% NEXIUM 20 mg (P<.05 vs omeprazole 20 mg) vs 87% omeprazole 20 mg (n=1960).†1,3

In 2 additional studies, one with NEXIUM 20 mg and one with NEXIUM 40 mg, NEXIUM healing rates vs omeprazole were compared: 92% NEXIUM 40 mg vs 90% omeprazole 20 mg (n=1148; P=NS), and 91% NEXIUM 20 mg vs 88% omeprazole 20 mg (n=1176; P=NS).†4,5

*Varying grades of EE defined as LA grades A, B, C, and D erosive esophagitis.

Data from multicenter, randomized, double-blind trials comparing oral doses of NEXIUM vs omeprazole, administered once daily to patients with endoscopically diagnosed EE.1–5

NEXIUM 40 mg, NEXIUM 20 mg, and omeprazole 20 mg are the FDA-approved doses for the healing of EE.

View healing data for NEXIUM vs omeprazole

References

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  2. Richter JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001;96:656–665.
  3. Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14:1249–1258.
  4. Schmitt C, Lightdale CJ, Hwang C, et al. Dig Dis Sci. 2006;51:844–850.
  5. Lightdale CJ, Schmitt C, Hwang C, et al. Dig Dis Sci. 2006;51:852–857.

In one study, healing rates in GERD patients with varying degrees of LA grades A-D of erosive esophagitis (EE) through 8 weeks were 93% NEXIUM 40 mg vs 89% lansoprazole 30 mg (n=5241; P<.0001).*1



*Primary end point from a multicenter, randomized, double-blind, parallel-group, 8-week trial comparing oral doses of NEXIUM 40 mg with lansoprazole 30 mg administered once daily to patients with endoscopically diagnosed EE.1

In a further study, healing rates in GERD patients with moderate-to-severe (LA grades C-D) EE through 8 weeks were 82% NEXIUM 40 mg vs 78% lansoprazole 30 mg (n=999; P=.007).†2

Primary end point from a multicenter, randomized, double-blind, parallel-group, 8-week trial comparing oral doses of NEXIUM 40 mg with lansoprazole 30 mg administered once daily to patients with endoscopically diagnosed EE.2

In 2 of the 4 pivotal studies, NEXIUM vs omeprazole for the healing of EE, P=NS.

NEXIUM 40 mg, NEXIUM 20 mg, and lansoprazole 30 mg are the FDA-approved doses for the healing of EE.

View healing data for NEXIUM vs lansoprazole

References

  1. Castell DO, Kahrilas PJ, Richter JE, et al. Am J Gastroenterol. 2002;97:575–583.
  2. Fennerty MB, Johanson JF, Hwang C, et al. Aliment Pharmacol Ther. 2005;21:455–463.

Two multicenter, randomized, double-blind, placebo-controlled, 4-arm trials were conducted in patients with endoscopically confirmed, healed erosive esophagitis (EE) to evaluate NEXIUM 40 mg (n=174), 20 mg (n=180),

10 mg (n=168), or placebo (n=171) once daily over 6 months of treatment.1

No additional clinical benefit was seen with NEXIUM 40 mg over NEXIUM 20 mg.

Patients remained in remission significantly longer and the number of recurrences of EE was significantly less in patients treated with NEXIUM compared to placebo.1

In both studies, the proportion of patients on NEXIUM who remained in remission and were free of heartburn and other GERD symptoms was well differentiated from placebo.1

No additional clinical benefit was seen with NEXIUM 40 mg over NEXIUM 20 mg.

Review “Maintenance of Healing Rates by Month” in figures 2 and 3 on pages 7 and 8 in the

Prescribing Information.

NEXIUM 20 mg is the FDA-approved dose for the maintenance of healing of EE.

NEXIUM 40 mg and NEXIUM 20 mg are the FDA-approved doses for the healing of EE.

Read the full Prescribing Information for NEXIUM.















Reference

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.















In patients with EE, NEXIUM provided day and night symptom relief over 24 hours.1-3

The percent of heartburn-free* days with NEXIUM 40 mg at Week 4 ranged from 73%–75%, based on patient diaries from 3 studies.†1-3

With NEXIUM 20 mg, the percent of heartburn-free days at Week 4 ranged from 69%–73%, based on patient diaries from 2 studies.†2,4

*Heartburn-free defined as patient-recorded symptom of “none.”

Secondary end points from 4 multicenter, randomized, double-blind trials comparing oral doses of NEXIUM vs omeprazole, administered once daily to patients with endoscopically diagnosed EE. Primary end point was healing of EE at week 8 (N=2425),1 (N=1960),2 (N=1148),3 (N=1175).4

NEXIUM 20 mg is the FDA-approved dose for the symptom relief of GERD.



NEXIUM 40 mg and NEXIUM 20 mg are the FDA-approved doses for the healing of EE. There is no correlation between symptom relief and the healing of EE with NEXIUM.

Review data for Symptom Relief.

References

  1. Richter JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001;96:656–665.
  2. Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14:1249–1258.
  3. Schmitt C, Lightdale CJ, Hwang C, et al. Dig Dis Sci. 2006;51:844–850.
  4. Lightdale CJ, Schmitt C, Hwang C, et al. Dig Dis Sci. 2006;51:852–857.

In patients with EE, NEXIUM provided day and night symptom relief over 24 hours.1-3

The percent of heartburn-free* nights with NEXIUM 40 mg at week 4 ranged from 85%–91%, based on patient diaries from 3 studies.†1-3



With NEXIUM 20 mg, the percent of heartburn-free nights at week 4 ranged from 84%–86%, based on patient diaries from 2 studies.†2,4

*Heartburn-free defined as patient-recorded symptom of “none.”

Secondary end points from 4 multicenter, randomized, double-blind trials comparing oral doses of NEXIUM vs omeprazole, administered once daily to patients with endoscopically diagnosed EE. Primary end point was healing of EE at week 8 (N=2425),1 (N=1960),2 (N=1148),3 (N=1175).4

NEXIUM 20 mg is the FDA-approved dose for the symptom relief of GERD.

NEXIUM 40 mg and NEXIUM 20 mg are the FDA-approved doses for the healing of EE. There is no correlation between symptom relief and the healing of EE with NEXIUM.

Review data for Symptom Relief.



References

  1. Richter JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001;96:656–665.
  2. Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14:1249–1258.
  3. Schmitt C, Lightdale CJ, Hwang C, et al. Dig Dis Sci. 2006;51:844–850.
  4. Lightdale CJ, Schmitt C, Hwang C, et al. Dig Dis Sci. 2006;51:852–857.

Safety Profile

NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.

Review the Safety Profile of NEXIUM and read Important Safety Information for NEXIUM.

In adults, the most frequently reported adverse reactions (ARs) with NEXIUM include headache, diarrhea, and abdominal pain.

In pediatric patients 1 to 17 years of age, the most frequently reported adverse reactions (ARs) with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence.1

In pediatric patients 1 month to 1 year, the most frequent adverse reactions (ARs) were abdominal pain, regurgitation, tachypnea, and increased ALT.

Review the Safety Profile of NEXIUM and read Important Safety Information for NEXIUM.

Reference

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines.1

Read the Important Safety Information and the full Prescribing Information for NEXIUM.

Reference

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

The steady-state pharmacokinetics of esomeprazole obtained after administration of 40 mg once daily to 4 patients each with mild (Child Pugh A), moderate (Child Pugh Class B), or severe (Child Pugh Class C) liver insufficiency were compared to those obtained in 36 male and female GERD patients with normal liver function. In patients with mild and moderate hepatic insufficiency, the AUCs were within the range that could be expected in patients with normal liver function. In patients with severe hepatic insufficiency, the AUCs were 2 to 3 times higher than in the patients with normal liver function. No dosage adjustment is recommended for patients with mild-to-moderate hepatic insufficiency (Child Pugh Classes A and B). However, in patients with severe hepatic insufficiency (Child Pugh Class C), a dose of 20 mg once daily should not be exceeded.1

Read the Important Safety Information and the full Prescribing Information for NEXIUM.

Reference    

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Drug Interactions

Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of esomeprazole 40 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant administration of NEXIUM with clopidogrel. See section 7.3 of the Prescribing Information.

May affect plasma levels of antiretroviral drugs—use with atazanavir and nelfinavir is not recommended; if saquinavir is used with NEXIUM, monitor for toxicity and consider saquinavir dose reduction. See section 7.1 of the Prescribing Information.

May interfere with drugs for which gastric pH affects bioavailability (eg, ketoconazole, iron salts, erlotinib, and digoxin). See section 7.2 of the Prescribing Information.

Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels. See section 7.3 of the Prescribing Information.

May increase systemic exposure of cilostazol and an active metabolite. Consider dose reduction. See section 7.3 of the Prescribing Information.

Please refer to the full Prescribing Information for NEXIUM for more information. 

Esomeprazole inhibits gastric acid secretion. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, atazanavir, iron salts, erlotinib, and digoxin).1

Read the full Prescribing Information for NEXIUM.

Reference    

  1. Prescribing Information for NEXIUM. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

2031108-3281229 Last Updated 8/16

Important Safety Information

  • NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
  • Symptomatic response to therapy does not rule out the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a proton pump inhibitor (PPI). In older patients, also consider an endoscopy
  • Acute interstitial nephritis has been observed in patients taking PPIs including NEXIUM. Discontinue NEXIUM if acute interstitial nephritis develops
  • PPI therapy may be associated with increased risk of Clostridium difficile-associated diarrhea. This diagnosis should be considered for diarrhea that does not improve
  • PPI therapy may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose (multiple daily doses) and long-term (a year or longer) therapy
  • Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including esomeprazole. These events included both new onset and exacerbations. If signs or symptoms consistent with CLE or SLE are noted with NEXIUM, discontinue and refer the patient to a specialist. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks
  • Avoid concomitant use of NEXIUM with clopidogrel, due to a reduction in plasma concentrations of the active metabolite of clopidogrel. When using NEXIUM consider alternative anti-platelet therapy
  • Daily treatment with any acid-suppressing medications over a long period of time (eg, longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B12). Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPI therapy and may require discontinuing PPI therapy
  • Concomitant use of NEXIUM and St. John’s wort or rifampin can substantially decrease NEXIUM concentrations. Avoid concomitant use
  • Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients
  • Concomitant use of NEXIUM and atazanavir or nelfinavir is not recommended. NEXIUM is expected to increase the plasma levels of saquinavir. Consider dose reduction of saquinavir
  • Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Esomeprazole may interfere with the absorption of drugs for which gastric pH affects bioavailability (eg, ketoconazole, iron salts, and digoxin)
  • NEXIUM may increase systemic exposure of cilostazol and one of its active metabolites. Consider dose reduction of cilastozol
  • NEXIUM I.V. should be used only when oral therapy with NEXIUM is not possible or appropriate
  • In adults, the most frequently reported adverse reactions (ARs) with NEXIUM include headache, diarrhea, and abdominal pain
  • The ARs reported at a frequency of 1% or greater with NEXIUM I.V. in clinical trials were headache, flatulence, nausea, abdominal pain, injection site reaction, diarrhea, dry mouth, dizziness/vertigo, constipation, and pruritus
  • In pediatric patients 1 to 17 years of age, the most frequently reported ARs with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence
  • In pediatric patients 1 to 11 months the most frequently reported ARs with NEXIUM include abdominal pain, regurgitation, tachypnea, and increased ALT

Approved Uses

NEXIUM 40 mg and 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD.

Prescribing Information with Medication Guide for NEXIUM. (PDF - 303 KB)

Prescribing Information for NEXIUM I.V. (PDF - 72 KB)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.